Applied DNA Reports Fiscal First Quarter 2018 Financial Results

February 8, 2018 4:05 PM

Company To Hold Conference Call and Webcast Today, Thursday, February 8, 2018 at 4:30 PM EST

STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), announced financial results for the fiscal 2018 first quarter ended December 31, 2017.

“We made significant progress in the first quarter on the execution of our growth strategy to expand our base of business in our core markets and broaden the application of our molecular tagging technology platform in adjacent markets, although our results reflect a slow start to the fiscal year,” stated Dr. James A. Hayward, chairman, president and CEO. “During and subsequent to the end of the fiscal first quarter, we developed new, long-term revenue opportunities, including the expansion of our cotton business into international markets with our first sale of a DNA Transfer System to an overseas ginner, and secured a contract award from TheraCann that leverages our cotton expertise to better track cannabis and its derivatives. Through our synthetic fiber customer GHCL, we have also gained the attention of the largest integrated producer of polyester fiber and yarn in the world on our CertainT platform and, with the upcoming filing of our Drug Master File with the FDA, we can now pursue revenue opportunities with pharmaceutical companies in a much more vigorous manner.

“Looking ahead to the balance of fiscal 2018, the expansion of our cotton business into a major overseas cotton-producing region reflects the growing importance brands owners, retailers and manufacturers place on the origin and authenticity of their cotton-based products and the continued adoption of our proven molecular taggant technology for textiles. This, together with continued adoption of CertainT by the synthetic fiber market and the imminent entry into the cannabis, pharmaceuticals, and other adjacent market opportunities, give us reason for continued optimism for this fiscal year. We, therefore, are reaffirming our base revenue guidance for fiscal 2018 of $6.5 million with a majority of revenue to be generated in our fiscal third and fourth quarters that are our peak cotton quarters,” concluded Dr. Hayward.

Fiscal First Quarter Financial Results:

Recent Operational Highlights:

Fiscal First Quarter 2018 Conference Call Information

The Company will hold a conference call and webcast to discuss its fiscal first quarter-end 2018 results on Thursday, February 8, 2018 at 4:30 PM ET. To participate on the conference call, please follow the instructions below. While every attempt will be made to answer investors’ questions on the Q&A portion of the call, due to the large number of expected participants, not all questions may be answered.

To Participate:

Live webcast:

Replay (available 1 hour following the conclusion of the live call through February 9, 2018):

For those investors unable to attend the live call, a copy of the presentation is expected to be posted by end of business on February 8, 2018 and available under the ‘Events and Presentations’ section of the company’s Investor Relations web site:

Information about Non-GAAP Financial Measures

As used herein, “GAAP” refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company’s historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

“EBITDA”- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

“Adjusted EBITDA”- is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based CertainT® platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac® and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Visit for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our lack of significant revenues, limited financial resources, limited market acceptance, history of net losses, shifting enforcement priorities of US federal laws relating to cannabis, market competition and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly report on Form 10-Q filed on February 8, 2018, which are available at Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.



December 31,


September 30,


Current assets:
Cash and cash equivalents $ 4,764,553 $ 2,959,781
Accounts receivable, net of allowance of $10,000 at December 31, 2017 and September 30, 2017, respectively 2,155,737 2,587,969
Inventories 314,088 326,468
Prepaid expenses and other current assets 540,048 366,954
Total current assets 7,774,426 6,241,172
Property and equipment, net 500,452 523,688
Other assets:
Deposits 62,453 61,626
Goodwill 285,386 285,386
Intangible assets, net 986,260 1,042,076
Total Assets $ 9,608,977 $ 8,153,948
Current liabilities:
Accounts payable and accrued liabilities $ 1,127,536 $ 944,133
Deferred revenue 342,960 351,735

Total current liabilities 1,470,496 1,295,868
Commitments and contingencies
Stockholders’ Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2017 and September 30, 2017 - -
Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2017 and September 30, 2017 - -
Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2017 and September 30, 2017 - -
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 30,112,057 and 27,377,057 shares issued and outstanding as of December 31, 2017 and September 30, 2017, respectively 30,112 27,377
Additional paid in capital 247,965,236 243,503,858
Accumulated deficit (239,856,867 ) (236,673,155 )
Total stockholders’ equity 8,138,481 6,858,080
Total Liabilities and Stockholders’ Equity $ 9,608,977 $ 8,153,948



Three Months Ended December 31,
2017 2016
Product revenues $350,133 $704,417
Service revenues 297,544 198,591
Total revenues 647,677 903,008
Cost of revenues 331,440 274,832
Operating expenses:
Selling, general and administrative 2,593,154 3,900,917
Research and development 740,067 518,628
Depreciation and amortization 157,648 161,977
Total operating expenses 3,490,869 4,581,522
LOSS FROM OPERATIONS (3,174,632) (3,953,346)
Other income (expense):
Interest income, net - 1,331
Other (expense) income, net (9,080) (9,369)
Loss before provision for income taxes (3,183,712) (3,961,384)
Provision for income taxes - -
NET LOSS $ (3,183,712) $ (3,961,384)
Net loss per share-basic and diluted $ (0.12) $ (0.16)
Weighted average shares outstanding- Basic and diluted 27,674,340 25,427,407



Three Months Ended December 31,

2017 2016
Net Loss $ (3,183,712) $ (3,961,384)
Interest income, net - (1,331)
Depreciation and amortization 157,648 161,977
Stock based compensation expense 231,113 1,458,020
Bad debt expense - 5,646
Total non-cash items 388,761 1,624,312
Consolidated Adjusted EBITDA (loss) $ (2,794,951) $ (2,337,072)


LHA Investor Relations

Sanjay M. Hurry, 212-838-3777



Dian Griesel Int'l.

Susan Forman, 212-825-3210






Source: Applied DNA Sciences, Inc.


Press Releases